What we are studying
The purpose of this research study is to determine whether an investigational drug, azeliragon (TTP488) is safe and beneficial in delaying or altering the decline in memory and daily functioning when given to people with mild Alzheimer’s disease (AD).
In this 23 month study, participants will be given either active study drug, azeliragon or placebo. A study partner is needed to participate.
Enrolled participants will receive $50 per completed visit to compensate them for transportation.